Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | LIFR | P42702 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | PTGFR | P43088 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603415 | 0.91 | GABRA5 (0.44) | NR1H4MAP2K4GABRA5 | |
| SCHEMBL4605381 | 0.88 | GPBAR1 (0.46) | MAP2K4CSNK2A2CSNK2BGABRA5GPBAR1 | |
| SCHEMBL4981559 | 0.87 | GABRA5 (0.46) | NR1H4GABRA5 | |
| SCHEMBL4981274 | 0.86 | NR1H4 (0.40) | NR1H4GABRA5 | |
| SCHEMBL14188874 | 0.86 | GABRA5 (0.49) | GABRA5 | |
| SCHEMBL28775774 | 0.85 | NR1H4 (0.45) | NR1H4LIFRGABRA5GPBAR1 | |
| SCHEMBL4981882 | 0.85 | GABRA5 (0.50) | NR1H4GABRA5 | |
| SCHEMBL14188870 | 0.84 | HPGD (0.47) | — | |
| SCHEMBL4605621 | 0.79 | GABRA5 (0.50) | MAP2K4GABRA5GPBAR1 | |
| SCHEMBL4594883 | 0.78 | GPBAR1 (0.47) | NR1H4LIFRGABRA5GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101277952-A | Isoxazole derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-01 | — | — | CN | disclosed |
| EP-1937674-A1 | ISOXAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-7378435-B2 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-27 | — | — | US | disclosed |
| WO-2007042420-A1 | ISOXAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082936-A1 | Aryl-isoxazole-4-carbonyl-indole-carboxylic acid amide derivatives | GABRA5, GABRA4, CHRNA5 | NR1H4 481/4885MAP2K4 3769/4885CSNK2A2 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.